Risks and side effects of islet transplantation

被引：78

作者：

Ryan E.A. ^{[1
]}

Paty B.W. ^{[1
]}

Senior P.A. ^{[1
]}

Shapiro A.M.J. ^{[1
]}

机构：

[1] Clinical Islet Transplant Program, Edmonton, Alta. T6G 2C8

来源：

Current Diabetes Reports | 2004年 / 4卷 / 4期

关键词：

Tacrolimus; Hypoglycemia; Sirolimus; Portal Vein Thrombosis; Islet Transplantation;

D O I：

10.1007/s11892-004-0083-8

中图分类号：

学科分类号：

摘要：

Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia, has been a net benefit Copyright © 2004 by Current Science Inc.

引用

页码：304 / 309

页数：5

共 55 条

[21]

Casey J.J., Lakey J.R.T., Ryan E.A., Et al., Portal venous pressure changes after sequential clinical islet transplantation, Transplantation, 74, pp. 913-915, (2002)

[22]

Markmann J.F., Rosen M., Siegelman E.S., Et al., Magnetic resonance defined periportal steatosis following intraportal islet transplantation: A functional footprint of islet graft survival?, Diabetes, 52, pp. 1591-1594, (2003)

[23]

Bhargava R., Senior P.A., Ackerman T.E., Et al., Prevalence of hepatic steatosis after islet transplantation and its relationship to graft function, Diabetes, 53, pp. 1311-1317, (2004)

[24]

Clayton H.A., Davies J.E., Pollard C.A., Et al., Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: The first 40 patients at the Leicester general hospital, Transplantation, 76, pp. 92-98, (2003)

[25]

Pyzdrowski K.L., Kendall D.M., Halter J.B., Et al., Preserved insulin secretion and insulin independence in recipients of islet autografts, N. Engl. J. Med., 327, pp. 220-226, (1992)

[26]

Robertson R.P., Lanz K.J., Sutherland D.E., Kendall D.M., Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis, Diabetes, 50, pp. 47-50, (2001)

[27]

Digon III B.J., Rother K.I., Hirshberg B., Harlan D.M., Sirolimus- induced interstitial pneumonitis in an islet transplant recipient, Diabetes Care, 26, (2003)

[28]

Johnson J.A., Kotovych M., Ryan E.A., Shapiro A.M., Reduced fear of hypoglycemia in successful islet transplantation, Diabetes Care, 27, pp. 624-625, (2004)

[29]

Eckhard M., Martin I., Eich T., Et al., Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function, Transplant. Proc., 34, pp. 1922-1924, (2002)

[30]

Tremblay F., Fernandes M., Habbab E., Et al., Malignancy after renal transplantation: Incidence and role of type of immunosuppression, Ann. Surg. Oncol., 98, pp. 785-788, (2003)

← 1 2 3 4 5 6 →